title: Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression.
abstract: The Polycomb transcription repressor BMI1 is highly expressed in human neuroblastomas and is required for the clonogenic self-renewal and tumorigenicity of human neuroblastoma cell lines. The molecular basis of BMI1 action in neuroblastoma cells is not well understood. Here we report that BMI1 has a critical role in stabilizing cyclin E1 by repressing the expression of FBXW7, a substrate-recognition subunit of the SCF E3 ubiquitin ligase that targets cyclin E1 for degradation. BMI1 binds to the FBXW7 locus in vivo and represses its mRNA expression. Overexpression of cyclin E1 or abrogation of FBXW7 induction rescues the cell-death phenotype of BMI1 knockdown. Moreover, MYCN, an oncoprotein in the pathogenesis of high-risk neuroblastomas, is able to counteract the death-inducing effect of BMI1 knockdown by activating CCNE1 transcription. We further show that high cyclin E1 expression is associated with Stage 4 neuroblastomas and poor prognosis in patients. These findings suggest a molecular mechanism for the oncogenic activity of BMI1 and MYCN in neuroblastoma pathogenesis and progression by maintaining cyclin E1 levels.
authors: Cancer Center and Department of Pathology, Cancer Center, Georgia Health Sciences University, Augusta, GA 30912, USA.
authors: L
authors: L
authors: Mao
authors: J
authors: J
authors: Ding
authors: A
authors: A
authors: Perdue
authors: L
authors: L
authors: Yang
authors: Y
authors: Y
authors: Zha
authors: M
authors: M
authors: Ren
authors: S
authors: S
authors: Huang
authors: H
authors: H
authors: Cui
authors: H-F
authors: HF
authors: Ding
mesh_terms: D014408:Biomarkers, Tumor / Q000502:physiology*; D018797:Cell Cycle Proteins / Q000235:genetics; D045744:Cell Line, Tumor; D019927:Cyclin E / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018450:Disease Progression; D044783:F-Box Proteins / Q000235:genetics; D000073979:F-Box-WD Repeat-Containing Protein 7; D006801:Humans; D000071447:N-Myc Proto-Oncogene Protein; D009363:Neoplasm Proteins / Q000502:physiology; D009447:Neuroblastoma / Q000401:mortality*; D009687:Nuclear Proteins / Q000502:physiology*; D015513:Oncogene Proteins / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D063150:Polycomb Repressive Complex 1; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000502:physiology*; D012097:Repressor Proteins / Q000502:physiology*; D025803:Tumor Suppressor Protein p14ARF / Q000502:physiology; D044767:Ubiquitin-Protein Ligases / Q000235:genetics
chemical_list: C069077:BMI1 protein, human; D014408:Biomarkers, Tumor; C475820:CCNE1 protein, human; C000614131:CDKN2A protein, human; D018797:Cell Cycle Proteins; D019927:Cyclin E; D019941:Cyclin-Dependent Kinase Inhibitor p16; D044783:F-Box Proteins; D000073979:F-Box-WD Repeat-Containing Protein 7; C513273:FBXW7 protein, human; C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D015513:Oncogene Proteins; D011518:Proto-Oncogene Proteins; D012097:Repressor Proteins; D025803:Tumor Suppressor Protein p14ARF; D063150:Polycomb Repressive Complex 1; D044767:Ubiquitin-Protein Ligases